替诺福韦及其在乙型肝炎病毒治疗中的潜力。
Tenofovir and its potential in the treatment of hepatitis B virus.
机构信息
Department of Public Medicine and Social Security - Section of Infectious Disease University of Naples "Federico II", Italy.
出版信息
Ther Clin Risk Manag. 2009 Feb;5(1):177-85. doi: 10.2147/tcrm.s3335. Epub 2009 Mar 26.
Abstract
Recent literature is reviewed about treatment of chronic hepatitis B virus (CHB), focusing on tenofovir disoproxil fumarate (TDF; Viread((R))), among the nucleotide and nucleoside analogs. TDF pharmacokinetics and pharmacodynamics, activity in respect of hepatitis B virus (HBV) multi-drug-resistant mutations, efficacy in treatment-naïve and treatment-experienced patients, and side effects are described. The most predictive response factors to TDF therapy are discussed and all available combination therapies to optimize clinical outcome in the various patient profiles are analyzed, such as compensated and/or decompensated cirrhotic patients. The use of TDF in pregnancy, and prophylaxis after exposure to HBV and post-liver transplantation are also evaluated.
摘要
本文主要综述了慢性乙型肝炎病毒（CHB）的治疗药物，重点介绍了核苷酸类似物和核苷类似物中的替诺福韦酯（TDF；Viread((R))）。本文描述了 TDF 的药代动力学和药效学、对乙型肝炎病毒（HBV）多药耐药突变的作用、在初治和经治患者中的疗效以及副作用。讨论了预测 TDF 治疗反应的最相关因素，并分析了所有可用的联合治疗方案，以优化各种患者人群的临床转归，如代偿和/或失代偿性肝硬化患者。本文还评估了 TDF 在妊娠期间的应用、HBV 暴露后的预防以及肝移植后的应用。
相似文献
1
Tenofovir and its potential in the treatment of hepatitis B virus.替诺福韦及其在乙型肝炎病毒治疗中的潜力。
Ther Clin Risk Manag. 2009 Feb;5(1):177-85. doi: 10.2147/tcrm.s3335. Epub 2009 Mar 26.
2
A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients.一项多中心、双盲、随机对照 III 期临床试验，旨在评估 DA-2802（替诺福韦二吡呋酯）和 Viread（富马酸替诺福韦二吡呋酯）在慢性乙型肝炎患者中的抗病毒活性和安全性。
J Korean Med Sci. 2022 Mar 21;37(11):e92. doi: 10.3346/jkms.2022.37.e92.
3
Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.长期使用以替诺福韦为基础的挽救疗法对核苷/核苷酸类似物治疗无效的慢性乙型肝炎患者的疗效。
J Gastroenterol. 2017 May;52(5):641-651. doi: 10.1007/s00535-016-1270-5. Epub 2016 Oct 3.
4
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.富马酸替诺福韦二吡呋酯（TDF）与恩曲他滨（FTC）/TDF 治疗拉米夫定耐药乙型肝炎：一项 5 年随机研究。
J Hepatol. 2017 Jan;66(1):11-18. doi: 10.1016/j.jhep.2016.08.008. Epub 2016 Aug 18.
5
Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.替诺福韦酯在拉米夫定耐药的慢性乙型肝炎患者中优于拉米夫定联合阿德福韦酯。
World J Gastroenterol. 2015 Mar 7;21(9):2746-53. doi: 10.3748/wjg.v21.i9.2746.
6
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.替诺福韦酯治疗慢性乙型肝炎单一感染
Hepatol Int. 2013 Jun;7(2):327-34. doi: 10.1007/s12072-011-9282-y. Epub 2011 Jun 19.
7
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany.替诺福韦酯治疗慢性乙型肝炎的有效性和安全性：德国一项为期3年的前瞻性现场实践研究
Dig Dis Sci. 2016 Oct;61(10):3061-3071. doi: 10.1007/s10620-015-3960-x. Epub 2015 Nov 14.
8
Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan.在接受化疗的乙型肝炎携带者中用预防性替诺福韦预防病毒复发：一项在台湾进行的 IV 期随机研究。
Hepatol Int. 2024 Apr;18(2):449-460. doi: 10.1007/s12072-023-10635-5. Epub 2024 Feb 20.
9
A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48.一项关于清众（富马酸替诺福韦二吡呋酯）与韦瑞德治疗慢性乙型肝炎的随机、双盲、双模拟、对照、多中心研究：第48周的第一阶段结果
Medicine (Baltimore). 2019 Aug;98(33):e16778. doi: 10.1097/MD.0000000000016778.
10
Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks.替诺福韦酯在中国慢性乙型肝炎患者中的应用：一项96周的多中心、双盲、双模拟临床试验结果
World J Clin Cases. 2021 Jun 26;9(18):4690-4699. doi: 10.12998/wjcc.v9.i18.4690.
引用本文的文献
1
Prevention of vertical transmission of hepatitis B: A retrospective review of a 5-year maternal-infant cohort in London.乙型肝炎垂直传播的预防：对伦敦一个为期5年的母婴队列的回顾性研究
J Paediatr Child Health. 2024 Sep;60(9):422-427. doi: 10.1111/jpc.16609. Epub 2024 Jul 2.
2
Analysis of hepatocellular carcinoma associated with hepatitis B virus.乙型肝炎病毒相关性肝细胞癌分析。
J Cell Mol Med. 2023 Aug;27(16):2271-2277. doi: 10.1111/jcmm.17867. Epub 2023 Jul 30.
3
Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities.病毒致癌作用的最新研究进展：现有预防和治疗实体。
Mol Pharm. 2023 Aug 7;20(8):3698-3740. doi: 10.1021/acs.molpharmaceut.2c01080. Epub 2023 Jul 24.
4
Tenofovir rescue therapy in pregnant females with chronic hepatitis B.替诺福韦挽救治疗慢性乙型肝炎孕妇。
World J Gastroenterol. 2015 Feb 28;21(8):2504-9. doi: 10.3748/wjg.v21.i8.2504.
5
Tenofovir in the management of chronic hepatitis B infection during pregnancy.替诺福韦在妊娠期间慢性乙型肝炎感染管理中的应用。
Balkan Med J. 2012 Jun;29(2):208-10. doi: 10.5152/balkanmedj.2012.007. Epub 2012 Jun 1.
6
Vertical transmission of hepatitis B virus: challenges and solutions.乙型肝炎病毒垂直传播：挑战与对策。
Int J Womens Health. 2014 Jun 10;6:605-11. doi: 10.2147/IJWH.S51138. eCollection 2014.
本文引用的文献
1
Hepatitis B virus infection.乙型肝炎病毒感染
N Engl J Med. 2008 Oct 2;359(14):1486-500. doi: 10.1056/NEJMra0801644.
2
[Treatment of chronic hepatitis B in HIV co-infected patients].[合并感染HIV患者的慢性乙型肝炎治疗]
Gastroenterol Clin Biol. 2008 Jan;32(1 Pt 2):S20-4. doi: 10.1016/S0399-8320(08)73261-5.
3
Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.在一名先前已对拉米夫定耐药的慢性乙型肝炎患者中，尽管长期抑制乙肝病毒DNA，但仍出现了恩替卡韦耐药突变：使用替诺福韦进行成功的挽救治疗。
Eur J Gastroenterol Hepatol. 2008 Aug;20(8):773-7. doi: 10.1097/MEG.0b013e3282f793d6.
4
5
Treatment of chronic hepatitis B: recommendations from an Italian workshop.慢性乙型肝炎的治疗：意大利研讨会的建议
Dig Liver Dis. 2008 Aug;40(8):603-17. doi: 10.1016/j.dld.2008.03.011. Epub 2008 May 22.
6
Review article: current antiviral therapy of chronic hepatitis B.综述文章：慢性乙型肝炎的当前抗病毒治疗
Aliment Pharmacol Ther. 2008 Jul;28(2):167-77. doi: 10.1111/j.1365-2036.2008.03731.x. Epub 2008 May 9.
7
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.拉米夫定与拉米夫定和阿德福韦酯联合治疗HBeAg阳性慢性乙型肝炎的比较。
J Hepatol. 2008 May;48(5):728-35. doi: 10.1016/j.jhep.2007.12.026. Epub 2008 Feb 29.
8
Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.替诺福韦联合拉米夫定作为乙型肝炎e抗原阳性肝硬化患者阿德福韦耐药慢性乙型肝炎的挽救治疗
Liver Int. 2008 Jul;28(6):814-20. doi: 10.1111/j.1478-3231.2008.01685.x.
9
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.在没有阿德福韦耐药突变的情况下，替诺福韦单药治疗对阿德福韦抗病毒治疗失败的乙肝患者有效。
J Hepatol. 2008 Mar;48(3):391-8. doi: 10.1016/j.jhep.2007.09.020. Epub 2008 Jan 3.
10
Potency of tenofovir in chronic hepatitis B: mono or combination therapy?替诺福韦在慢性乙型肝炎中的效力：单药治疗还是联合治疗？
J Hepatol. 2008 Mar;48(3):383-6. doi: 10.1016/j.jhep.2007.12.006. Epub 2007 Dec 31.
Zotero 插件